Baylor Miraca Genetics Laboratories, LLC (“BMGL”), a specialist in the development and commercialization of the highest quality genetic and genomic testing, today announced that Gary Huff will join the company as President and Chief Executive Officer. Mr. Huff is a clinical laboratory industry veteran with a proven track record of accelerating business growth and strategically aligning organizations to achieve outstanding results. 

Prior to joining BMGL, he was the Executive Vice President and Chief Operating Officer of Solstas Lab Partners; the largest private full-service clinical testing laboratory serving the southeast, owned by the New York-based private equity firm of Welsh, Carson, Anderson and Stowe.

Before leading Solstas, he was a senior executive for Laboratory Corporation of America. During his tenure, he held various leadership positions to include: North Atlantic Division Senior Vice President, National Toxicology Senior Vice President, Vice President of National Sales and Marketing Operations and Executive Director of Business Development.

Mr. Huff holds a Master's in Organizational Management, Six Sigma Lean Black Belt Certification, and he is a graduate of Indiana University with a Bachelor of Arts in General Studies/Psychology. He is also a graduate of the Executive Development Program at Elon University – Martha and Spencer Love School of Business.

BMGL was established as a joint venture between a Japan-based holding company, Miraca Holdings (“Miraca”), and Baylor College of Medicine (“Baylor”) on February 2, 2015. BMGL specializes in the development and commercialization of the highest quality genetic and genomic testing. BMGL offers a broad range of testing from traditional cytogenetics to chromosomal microarray analysis and next generation sequencing. BMGL is located in Houston’s Texas Medical Center with over 200 employees, over 3,000 tests available and clients in all 50 states and in 16 countries. BMGL’s lab is well-equipped with cutting edge diagnostic equipment, allowing it to efficiently generate the most accurate clinical genetic data. Through rigorous quality assurance, daily and monthly conferences, and close relationships with clinical partners, BMGL continuously improves diagnostic precision.

About Miraca Holdings

Miraca Holdings, a Japan-based holding company with group net sales of JPY204.7 billion (FYE 3/2015), is engaged in the following three business segments in the healthcare sector : (1) development, manufacture, and commercialization of in vitro diagnostics, (2) clinical laboratory testing, and (3) other healthcare related businesses, which are conducted by its subsidiaries and affiliates including Fujirebio Inc., a leading supplier of in vitro diagnostics in Japan, and SRL, Inc., Japan’s largest commercial laboratory. Miraca owns 60% stake of BMGL. For more information about Miraca Holdings, please visit their website.